SCHEMBL14804367

SCHEMBL14804367

Nc1cncc(-c2ccc3[nH]nc(C(=O)Nc4cccc(Cc5ccccc5)c4)c3c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 18/20 0.55
WNT1 P04628 12/20 0.55
CSNK2A1 P68400 2/20 0.54
CLK2 P49760 11/20 0.53
CLK3 P49761 10/20 0.53
DYRK3 O43781 1/20 0.51
MAP4K4 O95819 1/20 0.51
CDK1 P06493 1/20 0.51
CDK2 P24941 1/20 0.51
MARK3 P27448 1/20 0.51
GSK3B P49841 1/20 0.51
CSNK1G2 P78368 1/20 0.51
CDK5 Q00535 1/20 0.51
MAP4K2 Q12851 1/20 0.51
PRKAA1 Q13131 1/20 0.51
CAMK2B Q13554 1/20 0.51
CAMK2G Q13555 1/20 0.51
CAMK2D Q13557 1/20 0.51
NTRK3 Q16288 1/20 0.51
MARK2 Q7KZI7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14792911 0.93 DYRK1A (0.55) DYRK1AWNT1CLK2CLK3CDK2
SCHEMBL14792131 0.89 DYRK1A (0.67) DYRK1AWNT1CSNK2A1CLK2CLK3
SCHEMBL14804599 0.88 DYRK1A (0.67) DYRK1AWNT1CLK2CLK3
SCHEMBL14804382 0.88 DYRK1A (0.52) DYRK1AWNT1CSNK2A1CLK2CLK3
SCHEMBL14803969 0.88 DYRK1A (0.62) DYRK1AWNT1CSNK2A1CLK2CLK3
SCHEMBL14804428 0.87 DYRK1A (0.65) DYRK1AWNT1CSNK2A1CLK2CLK3
SCHEMBL14804376 0.87 DYRK1A (0.67) DYRK1AWNT1CLK2CLK3GSK3B
SCHEMBL14792633 0.86 DYRK1A (0.57) DYRK1AWNT1CLK2CLK3
SCHEMBL14804373 0.86 CSNK2A1 (0.59) DYRK1AWNT1CSNK2A1CLK2CLK3
SCHEMBL14804375 0.86 DYRK1A (0.74) DYRK1AWNT1CSNK2A1CLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130079329-A1 INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079329-A1 INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS WNT3, WNT1, WNT3A DYRK1A 733/4885WNT1 2/4885CSNK2A1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.